Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00CSQ
|
|||
| Former ID |
DAP001435
|
|||
| Drug Name |
Triclosan
|
|||
| Synonyms |
triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-9: 84] | Approved | [1] | |
| Infection of P. falciparum [ICD-11: 1F40] | Investigative | [2] | ||
| Trypanosomiasis [ICD-11: 1D51-1F53] | Investigative | [2] | ||
| Therapeutic Class |
Antibiotics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H7Cl3O2
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl
|
|||
| InChI |
1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
|
|||
| InChIKey |
XEFQLINVKFYRCS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 3380-34-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14214, 584337, 638158, 827598, 830483, 830851, 836967, 5664285, 7890716, 8153420, 10322303, 11109466, 12016155, 14720377, 14922470, 24698180, 24874395, 24886448, 26754498, 26759661, 29215355, 29224604, 47193732, 47207884, 48426058, 49674565, 49832484, 49903859, 49968902, 50109854, 53789200, 53800864, 56313852, 56314344, 57244094, 57260157, 57260158, 57322843, 57389809, 57652433, 79532964, 85172710, 85256706, 87350665, 87577595, 87692612, 91011813, 92308067, 92710097, 99445075
|
|||
| ChEBI ID |
CHEBI:164200
|
|||
| SuperDrug ATC ID |
D08AE04; D09AA06
|
|||
| SuperDrug CAS ID |
cas=003380345
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasmodium Enoyl-ACP reductase (Malaria fabI) | Target Info | Binder | [2], [3], [4], [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. | |||
| REF 3 | Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. | |||
| REF 4 | The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. | |||
| REF 5 | Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.